{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:26Z","timestamp":1790753786866,"version":"4.1.0"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Hepatitis B virus (HBV) infection is a public health threat worldwide, and there is no direct treatment yet available. In the event of infection, patients may present liver cirrhosis and cancer, which threaten the patients\u2019 health globally, especially in the Asia-Pacific region and China. In 2019, Chinese hepatopathologists updated the 2015 Guidelines for the Prevention and Treatment of Chronic Hepatitis B as the clinical reference. The other versions formulated by the American Association for the Study of Liver Diseases (2018 AASLD guidelines) (AASLD, 2018), <jats:xref>European Association for the Study of the Liver (2017<\/jats:xref> EASL guidelines) (EASL, 2017), and Asian-Pacific Association for the Study of the Liver (2015 APASL guidelines) (APASL, 2015) also provide clinical guidance. However, there are still some issues that need to be addressed. In the present study, the following aspects will be introduced successively: (1) Who should be treated in the general population according to the guidelines; (2) Treatment of specific populations infected with HBV; (3) Controversial issues in clinical practice; (4) Perspective.<\/jats:p>","DOI":"10.3389\/fmicb.2022.975584","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T10:04:50Z","timestamp":1662631490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Current treatment of chronic hepatitis B: Clinical aspects and future directions"],"prefix":"10.3389","volume":"13","author":[{"given":"Minmin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiebing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2012.07.011","article-title":"Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.","volume":"96","author":"Akbar","year":"2012","journal-title":"Antiviral Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3329\/bmrcb.v40i3.25229","article-title":"Hepatic necroinflammation and severe liver fibrosis in patients with chronic hepatitis B with undetectable HBV DNA and persistently normal alanine aminotransferase.","volume":"40","author":"Alam","year":"2014","journal-title":"Bangladesh Med. Res. Counc. Bull."},{"key":"B3","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.","volume":"67","author":"Berg","year":"2017","journal-title":"J. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection.","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.31026","article-title":"Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.","volume":"72","author":"Carey","year":"2020","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jhep.2018.03.021","article-title":"Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection.","volume":"69","author":"Caviglia","year":"2018","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"103389","DOI":"10.1016\/j.ebiom.2021.103389","article-title":"A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.","volume":"67","author":"Chang","year":"2021","journal-title":"EBioMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients.","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10620-009-0724-5","article-title":"Histological changes in chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal.","volume":"55","author":"Chen","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1172\/JCI135616","article-title":"Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.","volume":"130","author":"Cheng","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007","article-title":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version).","volume":"27","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3969\/j.issn.1001-5256.2019.09.007","article-title":"Diagnosis and treatment standard for hepatitis B virus infection after organ transplantation (2019 edition).","volume":"35","year":"2019","journal-title":"J. Clin. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/apt.15311","article-title":"High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.","volume":"50","author":"Choi","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/hep.31030","article-title":"EASL-AASLD HBV Treatment Endpoints Conference Faculty. (2020). Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger).","volume":"71","author":"Cornberg","year":"2019","journal-title":"J. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.1093\/cid\/ciw023","article-title":"Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.","volume":"62","author":"Dandri","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coviro.2018.03.006","article-title":"Why, who and when to start treatment for chronic hepatitis B infection.","volume":"30","author":"Dolman","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","article-title":"High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.","volume":"15","author":"Duan","year":"2021","journal-title":"Hepatol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.","volume":"67","year":"2017","journal-title":"J. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"719.e","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy.","volume":"18","author":"Fan","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e20211838","DOI":"10.1084\/jem.20211838","article-title":"Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV.","volume":"219","author":"Fang","year":"2022","journal-title":"J. Exp. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nm.4275","article-title":"Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B.","volume":"23","author":"Fisicaro","year":"2017","journal-title":"Nat. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/hep4.1247","article-title":"Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis.","volume":"2","author":"Ford","year":"2018","journal-title":"Hepatol. Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity.","volume":"66","author":"Giersch","year":"2017","journal-title":"J. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1136\/bmj.323.7308.334","article-title":"A new system for grading recommendations in evidence based guidelines.","volume":"323","author":"Harbour","year":"2001","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6588","DOI":"10.1038\/ncomms7588","article-title":"Trained immunity in newborn infants of HBV-infected mothers.","volume":"6","author":"Hong","year":"2015","journal-title":"Nat. Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3760\/cma.j.issn.1007-3418.2015.12.002","article-title":"The guideline of prevention and treatment for chronic hepatitis B: a 2015 update.","volume":"23","author":"Hou","year":"2015","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.","volume":"73","author":"Huang","year":"2021","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should Treatment Indications for Chronic Hepatitis B Be Expanded?","volume":"19","author":"Jeng","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s12072-021-10223-5","article-title":"APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.","volume":"15","author":"Kao","year":"2021","journal-title":"Hepatol. Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/v9050096","article-title":"Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks.","volume":"9","author":"Kennedy","year":"2017","journal-title":"Viruses"},{"key":"B34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12072-021-10285-5","article-title":"Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy.","volume":"16","author":"Kumar","year":"2022","journal-title":"Hepatol. Int."},{"key":"B36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir.","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e00183","DOI":"10.14309\/ctg.0000000000000183","article-title":"Correction to: Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase.","volume":"11","author":"Lee","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.23505","article-title":"Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology","volume":"51","author":"Lee","year":"2010","journal-title":"Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"9157455","DOI":"10.1155\/2022\/9157455","article-title":"Characteristics of CD8+ and CD4+ Tissue-Resident Memory Lymphocytes in the Gastrointestinal Tract.","volume":"2022","author":"Li","year":"2022","journal-title":"Adv. Gut Microbiome Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia.","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int."},{"key":"B41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12072-019-09989-6","article-title":"Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.","volume":"13","author":"Liaw","year":"2019","journal-title":"Hepatol. Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"B43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China.","volume":"97","author":"Liu","year":"2019","journal-title":"Bull. World Health Organ."},{"key":"B44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hep4.1859","article-title":"Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis.","volume":"6","author":"Liu","year":"2022","journal-title":"Hepatol. Commun."},{"key":"B45","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections.","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2016.09.007","article-title":"Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.","volume":"52","author":"Ormeci","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/jvh.13242","article-title":"Young Chinese children without seroprotective hepatitis B surface antibody could be at risk of hepatitis B virus infection through horizontal transmission.","volume":"27","author":"Pan","year":"2020","journal-title":"J. Viral Hepat."},{"key":"B50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3851\/IMP3261","article-title":"Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"684.e","DOI":"10.1053\/j.gastro.2015.11.050","article-title":"Hepatitis B Virus\u2013Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.","volume":"150","author":"Park","year":"2016","journal-title":"Gastroenterology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2893.2008.00989.x","article-title":"High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels.","volume":"15","author":"Park","year":"2008","journal-title":"J. Viral Hepat."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/apt.14352","article-title":"The negative impact of HBV\/HCV coinfection on cirrhosis and its consequences.","volume":"46","author":"Pol","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nm.3251","article-title":"Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.","volume":"19","author":"Rehermann","year":"2013","journal-title":"Nat. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","article-title":"Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.","volume":"69","author":"Rinker","year":"2018","journal-title":"J. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.","volume":"128","author":"Rivino","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/hep.24725","article-title":"Upper limits of normal for alanine aminotransferase activity in the United States population.","volume":"55","author":"Ruhl","year":"2012","journal-title":"Hepatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3760\/cma.j.issn.1009-9158.2013.05.003","article-title":"Reference intervals for common tests of liver function electrolytes and blood cell analysis of Chinese adults.","volume":"36","author":"Shang","year":"2013","journal-title":"Chin. J. Lab. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/v12070741","article-title":"Hepatitis C Virus and Hepatitis B Virus Co-Infection.","volume":"12","author":"Shih","year":"2020","journal-title":"Viruses"},{"key":"B63","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41395-018-0093-9","article-title":"Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir.","volume":"113","author":"Shin","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","article-title":"Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.","volume":"76","author":"Sonneveld","year":"2022","journal-title":"J. Hepatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jhep.2013.05.043","article-title":"Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C.","volume":"59","author":"Squadrito","year":"2013","journal-title":"J. Hepatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e020490","DOI":"10.1136\/bmjopen-2017-020490","article-title":"Long-term trends of liver cancer mortality by gender in urban and rural areas in China: an age-period-cohort analysis.","volume":"8","author":"Sun","year":"2018","journal-title":"BMJ Open"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.","volume":"18","author":"Sun","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/hepr.13535","article-title":"Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: data from Hong Kong.","volume":"50","author":"Tampi","year":"2020","journal-title":"Hepatol. Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3748\/wjg.v23.i31.5746","article-title":"Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase.","volume":"23","author":"Tan","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection.","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.jfma.2017.11.012","article-title":"Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B.","volume":"117","author":"Tseng","year":"2018","journal-title":"J. Formos. Med. Assoc."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/hep4.1794","article-title":"Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update.","volume":"5","author":"Valenti","year":"2021","journal-title":"Hepatol. Commun."},{"key":"B74","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide.","volume":"67","author":"Valery","year":"2018","journal-title":"Hepatology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e80585","DOI":"10.1371\/journal.pone.0080585","article-title":"Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT.","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"B76","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma.","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/hep.23424","article-title":"Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.","volume":"51","author":"Wu","year":"2010","journal-title":"Hepatology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"111064","DOI":"10.18632\/oncotarget.22347","article-title":"Systemic bioinformatics analysis of recurrent aphthous stomatitis gene expression profiles.","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/jvh.13174","article-title":"HEV-LFS: A novel scoring model for patients with hepatitis E virus-related liver failure.","volume":"26","author":"Wu","year":"2019","journal-title":"J. Viral Hepatitis"},{"key":"B81","doi-asserted-by":"publisher","first-page":"6027361","DOI":"10.1155\/2020\/6027361","article-title":"Th1\/Th2 Cells and Associated Cytokines in Acute Hepatitis E and Related Acute Liver Failure.","volume":"2020","author":"Wu","year":"2020","journal-title":"J. Immunol. Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg <100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation.","volume":"56","author":"Xie","year":"2021","journal-title":"J. Gastroenterol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.","volume":"100","author":"Yang","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"B84","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fimmu.2018.00472","article-title":"Hyper-Expression of PD-1 Is Associated with the Levels of Exhausted and Dysfunctional Phenotypes of Circulating CD161(++)TCR iV\u03b17.2(+) Mucosal-Associated Invariant T Cells in Chronic Hepatitis B Virus Infection.","volume":"9","author":"Yong","year":"2018","journal-title":"Front. Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"gutjnl","DOI":"10.1136\/gutjnl-2021-325915","article-title":"Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients.","author":"Zhang","year":"2022","journal-title":"Gut"},{"key":"B86","doi-asserted-by":"publisher","first-page":"850","DOI":"10.14218\/JCTH.2021.00046","article-title":"Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease.","volume":"9","author":"Zhang","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e43736","DOI":"10.1371\/journal.pone.0043736","article-title":"Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population.","volume":"7","author":"Zheng","year":"2012","journal-title":"PLoS One"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.975584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T10:04:55Z","timestamp":1662631495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.975584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":87,"alternative-id":["10.3389\/fmicb.2022.975584"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.975584","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"article-number":"975584"}}